{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:33:45Z","timestamp":1787027625616,"version":"build-2736575974"},"reference-count":99,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Chronic obstructive pulmonary disease (COPD) is one of the major causes of disability and death. Maintenance use of inhaled bronchodilator(s) is the cornerstone of COPD pharmacological therapy, but inhaled corticosteroids (ICSs) are also commonly used. This narrative paper reviews the role of ICSs as maintenance treatment in combination with bronchodilators, usually in a single inhaler, in stable COPD subjects. The guidelines strongly recommend the addition of an ICS in COPD subjects with a history of concomitant asthma or as a step-up on the top of dual bronchodilators in the presence of hospitalization for exacerbation or at least two moderate exacerbations per year plus high blood eosinophil counts (\u2265300\/mcl). This indication would only involve some COPD subjects. In contrast, in real life, triple inhaled therapy is largely used in COPD, independently of symptoms and in the presence of exacerbations. We will discuss the results of recent randomized controlled trials that found reduced all-cause mortality with triple inhaled therapy compared with dual inhaled long-acting bronchodilator therapy. ICS use is frequently associated with common local adverse events, such as dysphonia, oral candidiasis, and increased risk of pneumonia. Other side effects, such as systemic toxicity and unfavorable changes in the lung microbiome, are suspected mainly at higher doses of ICS in elderly COPD subjects with comorbidities, even if not fully demonstrated. We conclude that, contrary to real life, the use of ICS should be carefully evaluated in stable COPD patients.<\/jats:p>","DOI":"10.3390\/biom14020195","type":"journal-article","created":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T03:22:31Z","timestamp":1707189751000},"page":"195","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Inhaled Corticosteroids in Subjects with Chronic Obstructive Pulmonary Disease: An Old, Unfinished History"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8300-751X","authenticated-orcid":false,"given":"Andrea S.","family":"Melani","sequence":"first","affiliation":[{"name":"Respiratory Diseases Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Croce","sequence":"additional","affiliation":[{"name":"Respiratory Diseases Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia","family":"Fabbri","sequence":"additional","affiliation":[{"name":"Respiratory Diseases Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Messina","sequence":"additional","affiliation":[{"name":"Respiratory Diseases Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8351-3703","authenticated-orcid":false,"given":"Elena","family":"Bargagli","sequence":"additional","affiliation":[{"name":"Respiratory Diseases Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,6]]},"reference":[{"key":"ref_1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (2023, July 30). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Global Strategy for Prevention, Diagnosis and Management of COPD: 2023 Report. Available online: https:\/\/goldcopd.org\/2023-gold-report-2\/."},{"key":"ref_2","first-page":"CD002991","article-title":"Inhaled corticosteroids versus placebo for stable chronic obstructive pulmonary disease","volume":"3","author":"Yang","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_3","first-page":"CD006826","article-title":"Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease","volume":"2013","author":"Nannini","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1056\/NEJMoa1516385","article-title":"Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD","volume":"374","author":"Wedzicha","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"00950-2020","DOI":"10.1183\/23120541.00950-2020","article-title":"INTREPID: Single- versus multiple-inhaler triple therapy for COPD in usual clinical practice","volume":"7","author":"Halpin","year":"2021","journal-title":"ERJ Open Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.chest.2022.06.033","article-title":"Clinical Characteristics, Treatment Persistence, and Outcomes Among Patients with COPD Treated with Single- or Multiple-Inhaler Triple Therapy: A Retrospective Analysis in Spain","volume":"162","author":"Jamart","year":"2022","journal-title":"Chest"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.2147\/COPD.S370540","article-title":"Comparative Adherence and Persistence of Single- and Multiple-Inhaler Triple Therapies Among Patients with Chronic Obstructive Pulmonary Disease in an English Real-World Primary Care Setting","volume":"17","author":"Halpin","year":"2022","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e001585","DOI":"10.1136\/bmjresp-2022-001585","article-title":"Use and persistence of single and multiple inhaler triple therapy prescribed for patients with COPD in France: A retrospective study on THIN database (OPTI study)","volume":"10","author":"Deslee","year":"2023","journal-title":"BMJ Open Respir. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","article-title":"Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD","volume":"378","author":"Lipson","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1916046","article-title":"Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD","volume":"383","author":"Rabe","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1164\/rccm.202006-2618OC","article-title":"Reduced All-Cause Mortality in the ETHOS Trial of Budesonide\/Glycopyrrolate\/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study","volume":"203","author":"Martinez","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMoa063070","article-title":"Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease","volume":"356","author":"Calverley","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1164\/rccm.201911-2207OC","article-title":"Reduction in All-Cause Mortality with Fluticasone Furoate\/Umeclidinium\/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease","volume":"201","author":"Lipson","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"00615","DOI":"10.1183\/23120541.00615-2022","article-title":"Triple therapy in COPD: Understanding the data","volume":"9","author":"Suissa","year":"2023","journal-title":"ERJ Open Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1164\/rccm.201605-1014OC","article-title":"COPDGene Investigators. Acute Exacerbations and Lung Function Loss in Smokers with and without Chronic Obstructive Pulmonary Disease","volume":"195","author":"Dransfield","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2147\/COPD.S346591","article-title":"Frequency and Severity of Exacerbations of COPD Associated with Future Risk of Exacerbations and Mortality: A UK Routine Health Care Data Study","volume":"17","author":"Whittaker","year":"2022","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1801230","DOI":"10.1183\/13993003.01230-2018","article-title":"Inhaled corticosteroid containing combinations and mortality in COPD","volume":"52","author":"Vestbo","year":"2018","journal-title":"Eur. Respir. J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2147\/COPD.S350167","article-title":"A Pooled Analysis of Mortality in Patients with COPD Receiving Dual Bronchodilation with and without Additional Inhaled Corticosteroid","volume":"17","author":"Miravitlles","year":"2022","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/17476348.2020.1804364","article-title":"Endo-phenotyping of COPD patients","volume":"15","author":"Barnes","year":"2021","journal-title":"Expert Rev. Respir. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1164\/rccm.202201-0209PP","article-title":"Blood Eosinophils and Chronic Obstructive Pulmonary Disease: A Global Initiative for Chronic Obstructive Lung Disease Science Committee 2022 Review","volume":"206","author":"Singh","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.amjmed.2021.09.006","article-title":"The Use of Inhaled Corticosteroids for Patients with COPD Who Continue to Smoke Cigarettes: An Evaluation of Current Practice","volume":"135","author":"Adcock","year":"2022","journal-title":"Am. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1183\/13993003.01370-2015","article-title":"Blood eosinophils as a marker of response to inhaled corticosteroids in COPD","volume":"47","author":"Barnes","year":"2016","journal-title":"Eur. Respir. J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1136\/thoraxjnl-2019-214457","article-title":"Association between COPD exacerbations and lung function decline during maintenance therapy","volume":"75","author":"Kerkhof","year":"2020","journal-title":"Thorax"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1164\/rccm.201803-0405OC","article-title":"Long-Term Triple Therapy De-escalation to Indacaterol\/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial","volume":"198","author":"Chapman","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"517","DOI":"10.7326\/0003-4819-151-8-200910200-00004","article-title":"Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease Study Group. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: A randomized trial","volume":"151","author":"Lapperre","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1080\/17476348.2019.1601559","article-title":"Pharmacogenomics of chronic obstructive pulmonary disease","volume":"13","author":"Hersh","year":"2019","journal-title":"Expert Rev. Respir. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/thorax-2021-217736","article-title":"Th2 high and mast cell gene signatures are associated with corticosteroid sensitivity in COPD","volume":"78","author":"Faiz","year":"2023","journal-title":"Thorax"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1900521","DOI":"10.1183\/13993003.00521-2019","article-title":"The pharmacogenomics of inhaled corticosteroids and lung function decline in COPD","volume":"54","author":"Obeidat","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1165\/rcmb.2016-0101OC","article-title":"Susceptibility to Childhood Pneumonia: A Genome-Wide Analysis","volume":"56","author":"Hayden","year":"2017","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/S2213-2600(18)30058-4","article-title":"Susceptibility to corticosteroid-induced adrenal suppression: A genome-wide association study","volume":"6","author":"Hawcutt","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1164\/rccm.202003-0625ST","article-title":"Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline","volume":"201","author":"Nici","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2000351","DOI":"10.1183\/13993003.00351-2020","article-title":"Withdrawal of inhaled corticosteroids in COPD: A European Respiratory Society guideline","volume":"55","author":"Chalmers","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2213-2600(17)30207-2","article-title":"Frequency of exacerbations in patients with chronic obstructive pulmonary disease: An analysis of the SPIROMICS cohort","volume":"5","author":"Han","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1601446","DOI":"10.1183\/13993003.01446-2016","article-title":"Phenotypes of COPD patients with a smoking history in Central and Eastern Europe: The POPE Study","volume":"49","author":"Koblizek","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/j.jaci.2018.04.010","article-title":"Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease","volume":"141","author":"Yun","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Alshabanat, A., Zafari, Z., Albanyan, O., Dairi, M., and FitzGerald, J.M. (2015). Asthma and COPD Overlap Syndrome (ACOS): A Systematic Review and Meta Analysis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0136065"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/thoraxjnl-2020-214644","article-title":"Eosinophilia and fractional exhaled nitric oxide levels in chronic obstructive lung disease","volume":"77","author":"Annangi","year":"2022","journal-title":"Thorax"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.rmed.2016.09.015","article-title":"Incidence of oral thrush in patients with COPD prescribed inhaled corticosteroids: Effect of drug, dose, and device","volume":"120","author":"Dekhuijzen","year":"2016","journal-title":"Respir. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1081-1206(10)60711-9","article-title":"Impact of inhaled corticosteroid-induced oropharyngeal adverse events: Results from a meta-analysis","volume":"98","author":"Rachelefsky","year":"2007","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Henao, M.P., Kraschnewski, J.L., Bolton, M.D., Ishmael, F., and Craig, T. (2020). Effects of Inhaled Corticosteroids and Particle Size on Risk of Obstructive Sleep Apnea: A Large Retrospective Cohort Study. Int. J. Environ. Res. Public Health, 17.","DOI":"10.3390\/ijerph17197287"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.2147\/COPD.S286149","article-title":"Risk of Pneumonia Associated with Inhaled Corticosteroid in Patients with Chronic Obstructive Pulmonary Disease: A Korean Population-Based Study","volume":"15","author":"Lee","year":"2020","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"210075","DOI":"10.1183\/16000617.0075-2021","article-title":"Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD","volume":"30","author":"Miravitlles","year":"2021","journal-title":"Eur. Respir. Rev."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.cmi.2022.11.029","article-title":"Hospitalization for chronic obstructive pulmonary disease and pneumonia: Association with the dose of inhaled corticosteroids. A nation-wide cohort study of 52 100 outpatients","volume":"29","author":"Sivapalan","year":"2023","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1378\/chest.15-0627","article-title":"Discontinuation of inhaled corticosteroids in COPD and the risk reduction of pneumonia","volume":"148","author":"Suissa","year":"2015","journal-title":"Chest"},{"key":"ref_45","unstructured":"European Medicines Agency (EMA) (2023, July 30). Pharmacovigilance Risk Assessment Committee (PRAC), Recommendation 2016. Inhaled Corticosteroids (ICS) Containing Medicinal Products Indicated in the Treatment of Chronic Obstructive Pulmonary Disease (COPD), Available online: https:\/\/www.ema.europa.eu\/medicines\/human\/referrals\/inhaled-corticosteroids-containing-medicinal-products-indicated-treatment-chronic-obstructive."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1513\/AnnalsATS.201409-413OC","article-title":"Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD","volume":"12","author":"Crim","year":"2015","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1164\/rccm.201908-1550OC","article-title":"Inhaled Steroids, Circulating Eosinophils, Chronic Airway Infection, and Pneumonia Risk in Chronic Obstructive Pulmonary Disease. A Network Analysis","volume":"201","author":"Faner","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S2213-2600(16)30148-5","article-title":"Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: A patient-level meta-analysis","volume":"4","author":"Pavord","year":"2016","journal-title":"Lancet. Respir. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/15412555.2016.1238450","article-title":"The Risk of Sepsis with Inhaled and Oral Corticosteroids in Patients with COPD","volume":"14","author":"Ernst","year":"2017","journal-title":"J. Chronic Obstr. Pulm. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.2147\/COPD.S209273","article-title":"Inhaled Corticosteroids and Risk Of Tuberculosis In Patients With Obstructive Lung Diseases: A Systematic Review And Meta-Analysis Of Non-randomized Studies","volume":"14","author":"Castellana","year":"2019","journal-title":"Int. J. Chronic Obstruct. Pulm. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.chest.2023.06.014","article-title":"Risk Factors for Nontuberculous Mycobacterial Pulmonary Disease: A Systematic Literature Review and Meta-analysis","volume":"164","author":"Loebinger","year":"2023","journal-title":"Chest"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Opron, K., Begley, L.A., Erb-Downward, J.R., Freeman, C., Madapoosi, S., Alexis, N.E., Barjaktarevic, I., Graham Barr, R., Bleecker, E.R., and Bowler, R.P. (2021). Lung microbiota associations with clinical features of COPD in the SPIROMICS cohort. NPJ Biofilms Microbiomes, 7.","DOI":"10.1038\/s41522-021-00185-9"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1164\/rccm.202110-2241OC","article-title":"SPIROMICS Research Group. Lung Microbiota and Metabolites Collectively Associate with Clinical Outcomes in Milder Stage Chronic Obstructive Pulmonary Disease","volume":"206","author":"Madapoosi","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1164\/rccm.202009-3448OC","article-title":"Inflammatory Endotype-associated Airway Microbiome in Chronic Obstructive Pulmonary Disease Clinical Stability and Exacerbations: A Multicohort Longitudinal Analysis","volume":"203","author":"Wang","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jaci.2020.02.040","article-title":"The sputum microbiome, airway inflammation, and mortality in chronic obstructive pulmonary disease","volume":"147","author":"Dicker","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"230084","DOI":"10.1183\/16000617.0084-2023","article-title":"How inhaled corticosteroids target inflammation in COPD","volume":"32","author":"Lea","year":"2023","journal-title":"Eur. Respir. Rev."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Mohsin, R.U., Heerfordt, C.K., Ekl\u00f6f, J., Sivapalan, P., Saeed, M.I., Ingebrigtsen, Y.S., Nielsen, S.D., Harboe, Z.B., Iversen, K.K., and Bangsborg, J. (2022). Use of Inhaled Corticosteroids and Risk of Acquiring Haemophilus influenzae in Patients with Chronic Obstructive Pulmonary Disease. J. Clin. Med., 11.","DOI":"10.3390\/jcm11123539"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2147\/COPD.S386518","article-title":"Inhaled Corticosteroids in Patients with Chronic Obstructive Pulmonary Disease and Risk of Acquiring Streptococcus pneumoniae Infection. A Multiregional Epidemiological Study","volume":"18","author":"Heerfordt","year":"2023","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e001726","DOI":"10.1136\/bmjresp-2023-001726","article-title":"Inhaled corticosteroids and risk of lower respiratory tract infection with Moraxella catarrhalis in patients with chronic obstructive pulmonary disease","volume":"10","author":"Johnsen","year":"2023","journal-title":"BMJ Open Respir. Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1136\/thoraxjnl-2021-217160","article-title":"Use of inhaled corticosteroids and risk of acquiring Pseudomonas aeruginosa in patients with chronic obstructive pulmonary disease","volume":"77","author":"Ingebrigtsen","year":"2022","journal-title":"Thorax"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1164\/rccm.202102-0289OC","article-title":"Effects of Inhaled Corticosteroid\/Long-Acting \u03b22-Agonist Combination on the Airway Microbiome of Patients with Chronic Obstructive Pulmonary Disease: A Randomized Controlled Clinical Trial (DISARM)","volume":"204","author":"Takiguchi","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jaci.2015.07.036","article-title":"Exchange protein directly activated by cyclic AMP (EPAC) activation reverses neutrophil dysfunction induced by beta2-agonists, corticosteroids, and critical illness","volume":"137","author":"Scott","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s41030-023-00227-x","article-title":"Systemic Corticosteroids for Treating Respiratory Diseases: Less Is Better, but\u2026 When and How Is It Possible in Real Life?","volume":"9","author":"Melani","year":"2023","journal-title":"Pulm. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"8209978","DOI":"10.1155\/2023\/8209978","article-title":"Inhaled Corticosteroid Exposure and Risk of Cataract in Patients with Asthma and COPD: A Systematic Review and Meta-Analysis","volume":"2023","author":"Savran","year":"2023","journal-title":"J. Ophthalmol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41533-019-0138-6","article-title":"Incidence of type II diabetes in chronic obstructive pulmonary disease: A nested case-control study","volume":"29","author":"Gayle","year":"2019","journal-title":"NPJ Prim. Care Respir. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.chest.2019.11.007","article-title":"Comparative Effects of LAMA-LABA-ICS vs LAMA-LABA for COPD: Cohort Study in Real-World Clinical Practice","volume":"157","author":"Suissa","year":"2020","journal-title":"Chest"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41533-019-0150-x","article-title":"Inhaled corticosteroids in COPD and onset of type 2 diabetes and osteoporosis: Matched cohort study","volume":"29","author":"Price","year":"2019","journal-title":"NPJ Prim. Care Respir. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.4187\/respcare.10933","article-title":"Risk of Fracture and Osteoporosis in Patients with COPD and Inhaled Corticosteroids Treatment","volume":"68","author":"Zhang","year":"2023","journal-title":"Respir. Care"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2000515","DOI":"10.1183\/13993003.00515-2020","article-title":"Osteoporosis and fracture risk associated with inhaled corticosteroid use among Swedish COPD patients: The ARCTIC study","volume":"57","author":"Janson","year":"2021","journal-title":"Eur. Respir. J."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.chest.2017.07.002","article-title":"Long-term Use of Inhaled Corticosteroids in COPD and the Risk of Fracture","volume":"153","author":"Gonzalez","year":"2018","journal-title":"Chest"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/S0012-3692(15)31287-3","article-title":"Skin manifestations of inhaled corticosteroids in COPD patients: Results from Lung Health Study, II","volume":"126","author":"Tashkin","year":"2004","journal-title":"Chest"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"412","DOI":"10.7861\/clinmedicine.16-5-412","article-title":"Iatrogenic Cushing\u2019s syndrome due to drug interaction between glucocorticoids and the ritonavir or cobicistat containing HIV therapies","volume":"16","author":"Elliot","year":"2016","journal-title":"Clin. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1210\/jc.2015-1218","article-title":"Adrenal insufficiency in corticosteroids use: Systematic review and meta-analysis","volume":"100","author":"Broersen","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.anai.2022.01.001","article-title":"Secondary adrenal suppression related to high doses of inhaled corticosteroids in patients with severe asthma","volume":"128","author":"Lobato","year":"2022","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1901147","DOI":"10.1183\/13993003.01147-2019","article-title":"Oral steroid-sparing effect of high-dose inhaled corticosteroids in asthma","volume":"55","author":"Maijers","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1007\/s12325-021-01976-4","article-title":"Pharmacology Versus Convenience: A Benefit\/Risk Analysis of Regular Maintenance Versus Infrequent or As-Needed Inhaled Corticosteroid Use in Mild Asthma","volume":"39","author":"Aggarwal","year":"2022","journal-title":"Adv. Ther."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1089\/jamp.2020.1618","article-title":"Targeting the Small Airways with Inhaled Corticosteroid\/Long-Acting Beta Agonist Dry Powder Inhalers: A Functional Respiratory Imaging Study","volume":"34","author":"Watz","year":"2021","journal-title":"J. Aerosol. Med. Pulm. Drug Deliv."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"S440","DOI":"10.1016\/S0091-6749(98)70156-3","article-title":"Pharmacokinetics and pharmacodynamics of inhaled corticosteroids","volume":"101","author":"Derendorf","year":"1998","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/bcp.12637","article-title":"Inhaled corticosteroids: Potency, dose equivalence and therapeutic index","volume":"80","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"101828","DOI":"10.1016\/j.pupt.2019.101828","article-title":"Pharmacokinetics and pharmacodynamics of inhaled corticosteroids for asthma treatment","volume":"58","author":"Matera","year":"2019","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/bcp.14406","article-title":"Therapeutic index of inhaled corticosteroids in asthma: A dose-response comparison on airway hyperresponsiveness and adrenal axis suppression","volume":"87","author":"Brealey","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1111\/bcp.14633","article-title":"End-point selection to determine the airway-systemic ratio of inhaled corticosteroids in asthma","volume":"87","author":"Lipworth","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"102167","DOI":"10.1016\/j.pupt.2022.102167","article-title":"May a different kinetic mode explain the high efficacy\/safety profile of inhaled budesonide?","volume":"77","author":"Brattsand","year":"2022","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejphar.2005.12.049","article-title":"Corticosteroids and adrenoceptor agonists: The compliments for combination therapy in chronic airways diseases","volume":"533","author":"Sin","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1124\/molpharm.120.000146","article-title":"Transcriptome-Level Interactions between Budesonide and Formoterol Provide Insight into the Mechanism of Action of Inhaled Corticosteroid\/Long-Acting \u03b22-Adrenoceptor Agonist Combination Therapy in Asthma","volume":"99","author":"Mostafa","year":"2021","journal-title":"Mol. Pharmacol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/1465-9921-10-104","article-title":"The bioavailability and airway clearance of the steroid component of budesonide\/formoterol and salmeterol\/fluticasone after inhaled administration in patients with COPD and healthy subjects: A randomized controlled trial","volume":"10","author":"Dalby","year":"2009","journal-title":"Respir. Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"107368","DOI":"10.1016\/j.rmed.2023.107368","article-title":"Evolving to a single inhaler extrafine LABA\/LAMA\/ICS\u2014Inhalation technique and adherence at the heart of COPD patient care (TRIVOLVE)","volume":"218","author":"Brusselle","year":"2023","journal-title":"Respir. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e001814","DOI":"10.1136\/bmjresp-2023-001814","article-title":"Inhalation devices and inhaled corticosteroids particle size influence on severe pneumonia in patients with chronic obstructive pulmonary disease: A nationwide cohort study","volume":"10","author":"Heerfordt","year":"2023","journal-title":"BMJ Open Respir. Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1007\/s12325-021-01703-z","article-title":"Efficacy and Safety of Budesonide\/Glycopyrronium\/Formoterol Fumarate versus Other Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis","volume":"38","author":"Bourdin","year":"2021","journal-title":"Adv. Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1007\/s12325-022-02231-0","article-title":"Fluticasone Furoate\/Umeclidinium\/Vilanterol (FF\/UMEC\/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis","volume":"39","author":"Ismaila","year":"2022","journal-title":"Adv. Ther."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2147\/COPD.S401736","article-title":"High versus Medium Dose of Inhaled Corticosteroid in Chronic Obstructive Lung Disease: A Systematic Review and Meta-Analysis","volume":"18","author":"Tran","year":"2023","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.chest.2022.07.015","article-title":"Association of Inhaled Corticosteroids with All-Cause Mortality Risk in Patients with COPD: A Meta-analysis of 60 Randomized Controlled Trials","volume":"163","author":"Chen","year":"2023","journal-title":"Chest"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"853","DOI":"10.2147\/COPD.S189585","article-title":"Inhaled corticosteroid use by exacerbations and eosinophils: A real-world COPD population","volume":"14","author":"Vestbo","year":"2019","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2147\/COPD.S300299","article-title":"Adherence to Treatment Recommendations for Chronic Obstructive Pulmonary Disease\u2014Results from the Swedish National Airway Register","volume":"16","author":"Larsson","year":"2021","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.2147\/COPD.S375190","article-title":"Real-World Treatment of Patients Newly Diagnosed with Chronic Obstructive Pulmonary Disease: A Retrospective German Claims Data Analysis","volume":"17","author":"Buhl","year":"2022","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41533-023-00334-x","article-title":"Investigating the rationale for COPD maintenance therapy prescription across Europe, findings from a multi-country study","volume":"33","author":"Kocks","year":"2023","journal-title":"NPJ Prim. Care Respir. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S2213-2600(18)30327-8","article-title":"Triple therapy with budesonide\/glycopyrrolate\/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): A double-blind, parallel-group, multicentre, phase 3 randomised controlled trial","volume":"6","author":"Ferguson","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.2147\/COPD.S322036","article-title":"COPD Exacerbation History and Impact on Future Exacerbations\u20148-Year Retrospective Observational Database Cohort Study from Germany","volume":"16","author":"Vogelmeier","year":"2021","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1007\/s12325-023-02583-1","article-title":"DElaying Disease Progression in COPD with Early Initiation of Dual Bronchodilator or Triple Inhaled PharmacoTherapy (DEPICT): A Predictive Modelling Approach","volume":"40","author":"Singh","year":"2023","journal-title":"Adv. Ther."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/14\/2\/195\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:55:28Z","timestamp":1760104528000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/14\/2\/195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,6]]},"references-count":99,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["biom14020195"],"URL":"https:\/\/doi.org\/10.3390\/biom14020195","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,6]]}}}